Your fact-checks will appear here
Factors that increase the risk of cardiovascular disease and diabetes.
Published, peer‑reviewed meta‑analyses and systematic reviews have examined the effects of and glycemic measures including , but none of the identified meta‑analyses in the provided reporting perform ...
Clinical trials and systematic reviews present a conflicted picture: some studies report improvements in weight, lipids or markers of oxidative stress after ingestion, while other trials—especially in...
Dual GIP/GLP‑1 agonists like tirzepatide reduce weight and improve multiple cardiometabolic risk factors that plausibly lower heart‑failure events in obese patients, particularly HFpEF, via hemodynami...